ArriVent BioPharma, Inc. Common Stock (AVBP)
USD 25.76
(-4.31%)
USD 25.76
(-4.31%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | - | - | - |
| Cost of Revenue | - | - | - |
| Gross Profit | - | - | - |
| Operating Expenses | 74.59 Million | 36.9 Million | 8.69 Million |
| Selling, General and Administrative Expenses | 9.7 Million | 6.47 Million | 2.26 Million |
| Research and Development Expenses | 64.88 Million | 30.43 Million | 6.43 Million |
| Other Expenses | - | - | - |
| Cost and Expenses | 74.59 Million | 36.9 Million | 8.69 Million |
| Operating Income | -74.59 Million | -36.9 Million | -8.69 Million |
| Interest Expense | - | - | - |
| Income Tax Expense | - | -36.9 Million | -11.59 Million |
| Earnings before Tax | -69.33 Million | -36.9 Million | -51.6 Million |
| Net Income | -69.33 Million | -36.9 Million | -51.6 Million |
| Earnings Per Share Basic | -2.17 | -1.10 | -1.54 |
| Earnings Per Share Diluted | -2.17 | -1.10 | -1.54 |
| Weighted Average Shares Outstanding | 31.95 Million | 33.49 Million | 33.49 Million |
| Weighted Average Shares Outstanding (Diluted) | 31.95 Million | 33.49 Million | 33.49 Million |
| Gross Margin | - | - | - |
| EBIT Margin | - | - | - |
| Profit Margin | - | - | - |
| EBITDA | -74.59 Million | -36.9 Million | -51.6 Million |
| Earnings Before Tax Margin | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | 25.69 Million | 20.67 Million | 23.11 Million | 74.59 Million | 16.71 Million | 22.58 Million |
| Selling, General and Administrative Expenses | 3.91 Million | 3.69 Million | 3.1 Million | - | 2.43 Million | 2.22 Million |
| Research and Development Expenses | 21.77 Million | 16.97 Million | 20.01 Million | - | 14.28 Million | 20.35 Million |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 25.69 Million | 20.67 Million | 23.11 Million | 74.59 Million | 16.71 Million | 22.58 Million |
| Operating Income | -25.69 Million | -20.67 Million | -23.11 Million | -74.59 Million | -16.71 Million | -22.58 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | - | - | -23.11 Million | - | -16.71 Million | - |
| Earnings before Tax | -21.87 Million | -17.41 Million | -21.19 Million | -69.33 Million | -14.4 Million | -21.56 Million |
| Net Income | -21.87 Million | -17.41 Million | -21.19 Million | -69.33 Million | -14.4 Million | -21.56 Million |
| Earnings Per Share Basic | -0.65 | -0.52 | -0.63 | - | -0.43 | -0.64 |
| Earnings Per Share Diluted | -0.65 | -0.52 | -0.63 | - | -0.43 | -0.64 |
| Weighted Average Shares Outstanding | 33.5 Million | 33.49 Million | 33.49 Million | 33.49 Million | 33.49 Million | 33.49 Million |
| Weighted Average Shares Outstanding (Diluted) | 33.5 Million | 33.49 Million | 33.49 Million | 33.49 Million | 33.49 Million | 33.49 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -25.69 Million | -20.67 Million | -23.11 Million | - | -16.71 Million | -22.58 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
ARRRF
STG
JADE
6028
WPB
CBDG